A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
What is the purpose of this trial?
The objective of this study is to evaluate and compare the efficacy and safety of regorafenib vs. placebo in subjects with colorectal cancer after curative resection of liver metastasis and completion of all planned chemotherapy.
- 18 Years and older
- Bayer Healthcare Pharmaceuticals, Inc.
- Last Updated:
- Study HIC#: